GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (CHIX:BCARTb) » Definitions » 1-Year Sharpe Ratio

Biocartis Group NV (CHIX:BCARTB) 1-Year Sharpe Ratio : -67.81 (As of Jun. 21, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Biocartis Group NV 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-06-21), Biocartis Group NV's 1-Year Sharpe Ratio is -67.81.


Competitive Comparison of Biocartis Group NV's 1-Year Sharpe Ratio

For the Diagnostics & Research subindustry, Biocartis Group NV's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocartis Group NV's 1-Year Sharpe Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's 1-Year Sharpe Ratio falls into.


;
;

Biocartis Group NV 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.


Biocartis Group NV  (CHIX:BCARTb) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Biocartis Group NV 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Biocartis Group NV's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocartis Group NV Business Description

Traded in Other Exchanges
N/A
Address
Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV Headlines

No Headlines